Robert Croop

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

The Lancet · 2019 · First of 8 authors · Corresponding · 282 citations

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

New England Journal of Medicine · 2019 · 280 citations